City of Hope
City of Hope, Imugene Begin Trial of Oncolytic Virus in Advanced Solid Cancers
The partners will see if the oncolytic virus CF33-hNIS, dubbed Vaxinia, can increase PD-L1 tumor expression and make patients responsive to Merck's Keytruda.
Preclinical Data In Hand, City of Hope to Study Anti-TAG72 CAR T-Cell Therapy for Ovarian Cancer
At AACR, researchers described plans for an upcoming trial of an autologous CAR T-cell therapy infused directly into the peritoneal cavity of epithelial ovarian cancer patients.
Mustang Bio to Study CAR T-Cell, Oncolytic Virus Combination for Recurrent Brain Cancer Patients
The firm will launch a Phase I trial of the C134 oncolytic virus MB-108 followed by the autologous 13Rα2-targeted CAR T-Cell therapy MB-101 for advanced glioblastoma.
Natera Minimal Residual Disease Test Value Called Into Question by City of Hope CRC Patient Data
Premium
Based on the results of their new study, City of Hope researchers advised doctors against overreliance on Natera's Signatera assays for recurrence monitoring.
ASCO GU data on two Phase I studies of CAR T-cell therapies, one from Poseida Therapeutics and another from Mustang Bio, suggest preliminary efficacy in mCRPC.